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The objective of this study was to assess the level of awareness of prostate cancer (PCa) among the
general public and PCa patients in Europe and North America. A survey was undertaken across
four European countries (UK, Germany, Italy and Spain), and across the United States and Canada
in late 2007. In total, 1008 men with PCa and their partners (the ‘prostate sample’), and 911 men
without PCa and their partners (the ‘well sample’) participated in the survey, all aged X50 years.
Interviews were conducted through telephone, pen and paper, and online. Many people surveyed
(53%) thought that breast cancer is more common than PCa. Moreover, 1 in 10 people from the well
sample (10%) thought that PCa affects both men and women. When the prostate sample was asked
about their perceived level of risk of PCa before diagnosis, 50% believed that they/their husband or
partner were previously at low or very low risk, before they were diagnosed. Awareness of the
major risk factors for PCa (age and family history) was generally good, but respondents were less
clear about the role of other potential factors, such as smoking and drinking alcohol. This
international survey, thought to be largest of its type, shows that although patient and public
awareness of PCa is generally satisfactory, there is still a considerable lack of clarity about PCa risk
factors, and a danger for people to underestimate their own/their partner’s perceived risk for PCa.
Programmes to responsibly educate and inform men and their partners about risk factors,
prevalence and screening tools for PCa are required.
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Introduction
Prostate cancer (PCa), the most frequently diagnosed
cancer in men,
1,2 is diagnosed in almost 2000 men each
day worldwide, and one man is estimated to die from
the disease every 2min.
3 With 1 in 6 men in the United
States
4 and 1 in 11 men in Europe
5 estimated to be
diagnosed with PCa at some point in their lifetime, the
disease has been said to be already approaching
epidemic proportions.
2 Furthermore, because three-
quarters of all men diagnosed with PCa are aged X65
years
3 and with an aging population in many regions of
the world, the prevalence of the disease is likely to
increase, with concomitant socioeconomic and medical
implications.
5
Given this worrying situation, it is even more
concerning that men who seek knowledge about PCa
are faced with a lack of clarity and consensus in
some areas, specifically with regard to individual risk,
perceived risk factors, screening and treatment options.
Some of this uncertainty might likely stem from a
significant neglect of PCa compared with other cancers,
in particular breast cancer, both in the media and in
terms of clinical research, even though both the diseases
have a similar prevalence.
6,7 A recent survey of the
media revealed that there are 40% more articles focused
on breast cancer compared with PCa.
8 Moreover, the
considerable ‘research gap’ between PCa and breast
cancer is reflected by the fact that there are currently
more than 1000 active trials for the treatment of breast
cancer compared with only around half that number for
PCa.
9
Owing to the long gestation period of PCa, there is
significant interest in emerging therapies that reduce the
risk of developing the disease. A greater understanding
of the potential role of PCa risk reduction has been
provided by a number of trials, namely the Prostate
Cancer Prevention Trial (PCPT),
10,11 which showed that
intervention with finasteride therapy in men decreases
the period prevalence of PCa. In addition, the REduction
by DUtasteride of prostate Cancer Events (REDUCE)
12,13
trial showed that dutasteride reduces the risk of PCa in
men at increased risk of the disease. Further investiga-
tions may continue to shed light on the role of
pharmaceutical interventions in PCa risk reduction.
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www.nature.com/pcanIn view of the emerging and new interventions for
PCa, in this report, we ask what current level of
awareness exists among men and their partners about
PCa: the disease itself (prevalence, mortality and disease
characteristics), perceived risk factors and screening.
Which aspects of PCa awareness give cause for concern?
Moreover, do levels of awareness regarding these factors
change on diagnosis of PCa?
To our knowledge, although there have been notable
and important national surveys on PCa awareness,
14–16
there has been no large-scale international research on
public awareness of risk factors for PCa among those
affected by the disease (patients and their partners) and
among the general public since the survey results
published by Schulman et al.
17. This report surveyed
six European countries (France, Germany, Italy, Spain,
Sweden and the United Kingdom) and the United States,
and included 1400 men and women, aged between 40
and 70 years. Therefore, in what we believe is the most
recent and a unique investigation of its kind and scale,
we sought to understand current perceptions and
awareness of PCa among the PCa patients and the
general public in six countries: Canada, Germany, Italy,
Spain, the United Kingdom and the United States.
Here, we report the results of this international survey,
designed to evaluate awareness of PCa, that is, its
diagnosis, prevalence and risk factors. Men both with
and without PCa, and their partners, above the age of
50 years, were questioned. The structure of the current
survey is similar to that of Schulman et al.
17 in the
countries sampled and the types of questions asked (that
is, concerning risk factors and prevalence for PCa).
Therefore, although direct comparisons cannot be drawn
between studies, the present survey findings allow us to
learn about not only current levels of PCa awareness
among the patients and the public, but also about the
progress made in public awareness of PCa since 2003.
Materials and methods
Participants
GlaxoSmithKline commissioned the independent
research company Ipsos MORI (London, UK) to conduct
the survey in 2007. Ipsos is a leading multi-research
company with global reach, whose operatives have
extensive experience in collecting data from international
sources. The core research objectives were to measure the
awareness of the severity and implications of PCa, assess
knowledge of PCa compared with other cancers, and to
understand how the public perceive and contextualize
their level of risk.
Methodology
Interviews were conducted through telephone, pen and
paper and online, in UK, Germany, Italy, Spain, the
United States and Canada between October and
December 2007. The survey sample consisted of 1008
men with PCa and their partners (the ‘prostate cancer
sample’) and 911 men without PCa and their partners
(the ‘well sample’). All participants were aged X50
years. Although there were slightly more participants in
the PCa sample than in the well sample, the number of
PCa responders from each country were about equal.
Information about the mean age, education or comorbid-
ities of the patients was not obtained.
In terms of information collection, all the well samples
were surveyed through telephone, whereas the PCa
samples in Germany, Italy, Spain were surveyed through
pen and paper, the PCa sample in the United Kingdom
through telephone and the PCa samples in the United
States and Canada were questioned online.
Questionnaire
The questionnaire used for the survey is given in the
Appendix A. The questions were both prompted and
open ended.
The questions used in the survey were rigorously
drafted on the basis of advice from (including but not
limited to):
  A select group of physicians, interviewed at the
European Association of Urology meeting in 2007.
  A selection of PCa patient group’s representatives.
Questions were then screened for clarity and balance by
Ipsos MORI.
The questions were then translated for use in each of
the individual countries. The questions were tested by
pilots in each market, which threw up any areas of
confusion, which were then refined further.
Where appropriate, questions were asked to all
respondents (question sample is detailed with each
question in appendix and in Results below).
Results
Results have been split out, where differences pertain, for
the well sample and the PCa sample, and according to
country surveyed.
PCa prevalence
The total sample was asked, ‘Which one of the following
is the most common form of cancer in men in this
country?’ from a list of common cancer types including
bladder, lung and colorectal cancer (Q1). All groups said
that they thought PCa was the most common cancer type
over and above the other options, with 65% of the total
sample giving this response.
When asked, ‘Which one of the following is more
common in this country, breast cancer in women or PCa
in men?’ (Q2), 53% of the total sample said breast cancer
and 18% said PCa (Figure 1). Of note, 63% of the well
sample said that they thought breast cancer was more
common than PCa compared with 43% of the PCa
sample.
PCa mortality
The well sample were asked ‘In your opinion, among
those who have ever suffered from PCa, what percentage
of them actually die from the disease, as opposed to old
age or another cause of death?’ (Q3). The well sample
questioned believed that around one-third of men (32%)
will die from PCa. In Italy, they were more optimistic
than this, giving an average figure of 26%.
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The well sample was asked, ‘As far as you know, does
PCa only affect ‘‘men’’, only affect ‘‘women’’ or both?’
(Q4). Overall, 1 in 10 people (10%) said that they thought
PCa affects both men and women (Figure 2). In North
America, this figure was higher, at 16%. In Europe, 7% of
people thought that PCa affects men and women, 2%
said ‘Don’t know’ and 0.5% said that they thought that
PCa only affects women.
PCa signs and risk factors
To attempt to understand the participant’s contextualiza-
tion of PCa risk, the prostate sample was asked ‘Before
you were diagnosed with PCa, how much at risk did
‘‘you’’/‘‘your husband/partner’’ believe ‘‘you were’’/
‘‘he was’’ of developing PCa? To assess this among the
well sample, they were asked ‘Generally speaking, how
much at risk of PCa do you believe ‘‘you are’’/‘‘your
husband/partner is’’ compared with an average man of
the same age?’ All groups were given the options ‘Very
low, low, quite high risk, very high risk’ (Q5). Among the
total sample, almost half (43%) believed that this risk was
low or very low (Figure 3). Among the prostate sample,
50% believed that they/their husband or partner, were at
low or very low risk before they were diagnosed.
As a follow-up to this question, those in the total
sample who responded as ‘low’ were asked ‘And why do
you think your risk is low?’ (Q6), 26% of the total sample
answered without any firm response (Figure 4)—11%
said ‘Never thought about it,’ 10% said ‘I have no health
problems’ and 5% said ‘It won’t happen to me.’
Figure 2 Responses of participants (well sample) when they were
asked ‘who does prostate cancer affect: men, women or both?’
Green shading: only men; Pink shading: only women; Navy
shading: both; Yellow shading: don’t know. The color reproduction
of this figure is available on the html full text version of the paper.
Figure 3 Perceptions of prostate cancer risk among respondents
(split by sample). Green shading: very low risk; Pink shading: low
risk; Navy shading: quite low risk; Yellow shading: very high risk.
The color reproduction of this figure is available on the html full
text version of the paper.
Figure 4 Reasons cited for perceived low prostate cancer risk
among those who answered ‘low’ to the previous question (split by
sample). Green bars: prostate cancer sample; Navy bars: well
sample. The color reproduction of this figure is available on the
html full text version of the paper.
Figure 1 Perceptions of respondents (grouped by sample) when
asked if they thought prostate cancer or breast cancer was more
common in their country. Green bars: breast cancer is more
common; Navy bars: prostate cancer is more common. The color
reproduction of this figure is available on the html full text version
of the paper.
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groups were ‘lifestyle factors’, ‘no family history’ and
‘I have regular checkups’. Of note, 21% of the prostate
sample cited family history as a reason for why they
thought their/their partner’s risk was high/low com-
pared with 16% of the well sample.
Of those who had answered ‘high’ to question Q5, the
main reason cited by the total sample for their believing
they had this level of risk was ‘genetic reasons’, for
example, ‘father had it (42%)’. The main reason cited by
the well sample was ‘age’, that is, ‘being older (25%)’.
The total sample was asked ‘In your opinion, which of
the following factors, if any, could mean that a person
becomes more likely to develop PCa?’ (Q7). Age (84%)
and family history (77%) were the most popular
responses, whereas 43 and 36% of people thought that
smoking and drinking, respectively, were factors that
could increase a person’s risk of PCa.
PCa screening
Question 8 asked the total sample: ‘And in your opinion,
which of the following, if any, can men do to reduce their
likelihood of developing PCa?’ The list of prompted
options to this question included ‘exercise regularly, eat
plenty of fruit and vegetables, have regular checkups/
screening, not carrying a mobile phone in their pockets’.
Most people (94%) thought that the main thing that men
can do to reduce their prostate PCa risk is to go for
regular screening. This was closely followed by healthy
diet (77%) and regular exercise (66%). Of note, 14% of
people who were asked this question thought that not
carrying a mobile phone in their pocket would reduce
men’s risk of PCa.
In Germany specifically, nearly one-third of those
questioned believed that carrying a mobile phone in their
pocket could increase a person’s risk of developing PCa.
When asked from a list of options (Q9; including stool
sample test, sperm count, PSA test, CRP (C-reactive
protein) test), ‘Which, if any, of the following is used to
screen for PCa?’, even when prompted, 31% did not cite
the PSA test.
Discussion
The current survey results indicate that awareness of
PCa among European and North American men and
their partners is generally good, but there are some
specific areas of concern. Moreover, the survey reveals
many interesting disparities between the well sample
and the PCa sample, and also some specific country
differences.
It is noteworthy that people’s awareness of PCa, its
prevalence and risk factors is generally good, and has
improved somewhat since the time of the last published
survey of this kind of which we are aware—that
reported by Schulman et al.
17
Awareness of PCa prevalence
With respect to awareness of the prevalence of PCa, the
majority of people (65%) knew that PCa is the most
common cancer in men. In this respect, people’s knowl-
edge is accurate, as PCa is the most commonly diagnosed
cancer in men in Europe, and in the United States and
Canada.
1,3,4
These findings point to considerable improvement in
PCa awareness since the report by Schulman et al.
16 in
2003, in which it was revealed that only 39% of men and
28% of women spontaneously mentioned PCa when
asked what types of cancer they were aware of compared
with 79% of people who mentioned breast cancer. The
present findings indicate that many people questioned
knew, albeit when prompted, that PCa is the most
common form of cancer in men.
However, it is interesting that the majority of people
(53%) think that breast cancer is more common than PCa,
especially as PCa is actually more common than breast
cancer in one-third of the countries surveyed, that is, in
the United States and Italy.
1,6 In the remaining countries
surveyed, the prevalence of PCa is roughly equivalent to
that of breast cancer, with age-standardized PCa inci-
dence rates for Germany, the United Kingdom, Spain and
Canada ranging from an average of 93 to 124 cases per
100000 men.
1,6 These findings are concordant with those
of a recent survey in the United States conducted by the
Prostate Cancer Foundation (2006),
14 which revealed that
nearly three-quarters of 1572 people questioned believed
that PCa was less common among men than breast
cancer is among women.
It is interesting that the levels of awareness about
the incidence of PCa in the present study is lowest in
Spain and in Germany compared with that in other
European countries questioned, where 62 and 57%,
respectively, think that breast cancer is more common
than PCa. In Spain, even among men with PCa, 66%
believed that breast cancer is more common than PCa.
The finding that breast cancer is thought to be more
common than PCa is perhaps attributable to the more
widespread publicity that breast cancer achieves com-
pared with PCa. This fact may also be because of the
etiology of the disease, as although breast cancer often
causes deaths of women under the age of 45 years,
7
PCa usually affects a rather different demographic, and
most commonly affects men over the age of 50 years.
2
However, whatever may be the cause for this disparity,
it is undoubted that public education programmes
should address this issue.
Awareness of PCa mortality rates
People’s awareness of mortality rates was good, with
those questioned believing that about one-third of men
(32%) with PCa will die from the disease, and this figure
is fairly accurate. More than 200000 men each year die
from PCa worldwide.
1,2 Since 1995, the number of men
dying from PCa in Europe has increased by 16%.
1 This
may be because of a large increase in the numbers of men
reaching older ages—when men are more likely to
develop PCa.
5
Awareness of PCa disease characteristics
One of the most worrying findings from this survey
was that 1 in 10 people (10%) questioned think that
PCa affects both men and women, and 1% of those
questioned did not know whether it affects men or
women. The United States and Canada had the highest
proportion of people who believed that PCa affected men
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feasible that by the structuring of the question, that is,
‘As far as you know, does PCa only affect ‘‘men’’, only
affect ‘‘women’’ or both?’ respondents understood that
indeed, PCa does affect the quality of life of both men
and women. Nevertheless, further investigation is
warranted to clarify this issue.
PCa signs and risk factors: age and family history
The survey highlighted that people had a good knowl-
edge of the most common risk factors for PCa, such as
age (84%) and family history (77%). Therefore, when
considering these factors alone, people’s awareness of
risk factors was accurate. A man’s risk of developing PCa
increases in proportion to his age, with about three-
quarters of all cases diagnosed being in men aged X65
years.
3 Moreover, family history is known to be a strong
risk factor for PCa.
18 Having a first-degree relative with
PCa significantly increases the risk of developing the
disease compared with those having no first-degree
relatives with the disease.
18 For example, if you have a
father or brother with Pca, you have two to three times
the risk of developing the disease compared with those
having no first-degree relative affected. If you have a
father or brother with early onset PCa (which develops
under the age of 60 years), you have a fourfold increase
in risk compared with those having no first-degree
relative affected. Finally, if you have more than one first-
degree relative with early onset PCa, you have a ninefold
increase in risk of developing PCa.
18
PCa signs and risk factors: smoking and drinking
However, although people’s knowledge of age and
family history was relatively good, the responses relating
to smoking and drinking would seem to reflect the lack
of clarity on the role of these factors. Of those questioned,
43 and 36% of people think that smoking and drinking,
respectively, are risk factors for PCa. There is no clear
role for these risk factors in the development of PCa.
2
However, as these factors have a large influence on the
etiology of so many other diseases and cancer types, it is
perhaps understandable that people have misconcep-
tions about their influence on the development of PCa.
People’s understanding of the main risk factors for PCa
seems to have improved considerably since the survey
reported by Schulman et al.
17 However, again, this is
clearly an area in which public education and awareness
programmes are required.
PCa signs and risk factors: other issues mentioned
It must be noted that while this survey did not include a
prompted option to state race as a risk factor for PCa,
respondents were given the option to spontaneously cite
other factors that they believed to be PCa risk factors.
Despite this, it is interesting that none mentioned race as
a risk factor, although recent estimates show that Black
men have more than one-and-a-half times the risk for
developing PCa than White men.
19 Black men would
therefore be a particularly salient target for disease
education and awareness programmes.
Remarkably, 14% of people thought that they could
reduce their risk of PCa by ‘not carrying a mobile phone
in their pocket’. In Germany, this figure was highest of all
the countries surveyed, with nearly one-third (28%) of
those questioned believing that this was the case. No
clear relationship has been established between the use
of mobile phones and the development of cancer.
20
PCa signs and risk factors: underestimating your own risk
One of the most important and interesting finding from
this survey was that many men may be underestimating
their own risk of PCa and not contextualizing this risk.
The survey revealed that many people (43%) believe that
their risk of PCa is low or very low—even many men
with PCa believed they were at low risk before they were
diagnosed. However, most men believe that they have an
average (also 43%) risk of developing PCa. Although
difficult to quantify, the current consensus is that 1 in
6 men in the United States
4 and 1 in 11 men in Europe
5
will develop clinical PCa in their lifetime.
When the total sample was asked what their reasons
for thinking they previously had a low level of the risk of
developing PCa were, 26% said that they had either
‘Never thought about it’ or claimed ‘I have no health
problems’ or believed ‘It won’t happen to me.’
Screening for PCa
Most people think that the main thing that men can do to
reduce their PCa risk is to go for regular screening (94%).
These data indicate that the survey participants had a
very good awareness of screening. However, a note of
caution should be added, as this finding may also point
to some lack of clarity among the public concerning
screening, and to a need for increased education.
Although it is true that undergoing regular screening
may allow identification of the precursors to PCa or
diagnose PCa at early stages, thereby indirectly reducing
a man’s risk of developing the disease and/or reduced
PCa-related mortality, clearly, screening does not reduce
the risk of developing PCa per se. Moreover, the recently
published ERSPC trial
21 results showed that screening
decreased PCa-related mortality by 20%; however, an
increase in PCa over diagnosis and over treatment was
observed. Further analyses are thus needed to determine
the optimal screening interval in consideration of the
PSA value at the first screening and of previously
negative results on biopsy.
21
It should be acknowledged that there were certain
limitations to the survey, notably that no information
about the education or the comorbidities of the patients
was recorded. Moreover, although all participants were
aged X50 years, no break down of ages was available.
This prevents stratification of the data by these factors,
thereby limiting interpretations of the data in this way.
Future surveys of this type should include recording of
these data and may reveal findings of interest.
Conclusions
Since the report by Schulman et al.
17, awareness of PCa
seems to have improved somewhat, with respect to the
disease itself (gestation time, prevalence and mortality
rates), individual risk, perceived risk factors and screen-
ing. However, there are still a proportion of men and
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facts. Even more worrying is the finding of the survey
that many men perceive their risk of developing PCa to
be either low or average. Again, this is a clear area of
concern, and as such a focus for future disease education
and awareness programmes.
There also seems to be considerable disparity between
the countries surveyed in terms of PCa awareness,
particularly with regard to PCa prevalence and the
disease itself (that is, who does PCa affect?). We would
recommend that programmes to responsibly educate and
inform men and their partners about PCa are urgently
required to bridge the gap in awareness between PCa
and other cancers, and that these awareness programmes
are sufficiently sensitive to take into account these
country-specific differences.
Conflict of interest
The survey reported in this paper was commissioned
and funded by GlaxoSmithKline. Professor John
Fitzpatrick is a consultant to GlaxoSmithKline, Claire L
Brough is an employee of GlaxoSmithKline. Medical
writing support in the preparation of this manuscript
was provided by Anna L Saggerson and funded by
GlaxoSmithKline. Professor Roger Kirby has no conflicts
of interest.
References
1 Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P.
Estimates of the cancer incidence and mortality in Europe in
2006. Ann Oncol 2007; 18: 581–592.
2 Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J
et al. Human prostate cancer risk factors. Cancer 2004; 101 (Suppl):
2371–2490.
3 Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics
2002. CA Cancer J Clin 2005; 55: 74–108.
4 Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer
statistics, 2007. CA Cancer J Clin 2007; 57: 43–66.
5 Schulman C. The aging male: a challenge for urologists. Curr
Opin Urol 2000; 10: 337–345.
6 Globocan 2002 database. http://www-dep.iarc.fr/GLOBOCAN/
Table2_sel.htm.
7 Kamangar F, Dores GM, Anderson WF. Patterns of cancer
incidence, mortality, and prevalence across five continents:
defining priorities to reduce cancer disparities in different
geographic regions of the world. J Clin Oncol 2006; 24: 2137–2150.
8 Number of stories containing the search terms ‘prostate cancer’
or ‘breast cancer’, years 2006–2007. Source: Google advanced
news archive search.
9 Clinical Trials.gov. http://clinicaltrials.gov
10 Thomson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM,
Lucia MS et al. Assessing prostate cancer risk: results from
the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98:
529–534.
11 Thompson IM. The influence of finasteride on the development
of prostate cancer. N Engl J Med 2003; 349: 215–224.
12 Gomella L. Chemoprevention using dutasteride: the REDUCE
trial. Curr Opin Urol 2005; 15: 29–32.
13 Andriole G, Bostwick D, Gomella L, Marberger M, Montorsi F,
Pettaway C et al. Further analyses from the REDUCE Prostate
Cancer Risk Reduction Trial. JU r o l2009; 181 (Supplement): 555.
14 Men Silent About Cancer—Until Women Step In. Men’s Health
Survey sponsored by Gilette. Press release, 16 June 2006
http://www.prostatecancerfoundation.org/site/c.itIWK2OSG/
b.1778841/k.6564/PR_June_16_2006.htm
15 Patient survey shows most popular treatments, side effect
prevalence and patient preferences for information. Annual
Prostate Cancer/Men’s Health Survey Released. 6 May
2006 http://www.fightprostatecancer.org/site/News2?page¼
NewsArticle&id¼6929
16 Fitzpatrick J, Corcoran N, Fitzpatrick JM. Prostate cancer: how
aware is the public? Br J Urol 1998; 82: 43–48.
17 Schulman C, Kirby R, Fitzpatrick J. Awareness of prostate cancer
among the general public: findings of an independent interna-
tional survey. Eur Urol 2003; 44: 294–302.
18 Johns LE, Houlston RS. A systematic review and meta-analysis
of familial prostate cancer risk. BJU Int 2003; 91: 789–794.
19 SEER database. (http://seer.cancer.gov/statfacts/html/prost.html)
20 Moulder JE, Foster KR, Erdreich LS, McNamee JP. Mobile
phones, mobile phone base stations and cancer: a review. Int J
Radiat Biol 2005; 81: 189–203.
21 Schro ¨der FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S,
Nelen V et al. Screening and prostate-cancer mortality in a
randomized European study. N Engl J Med 2009; 360: 1320–1328.
This work is licensed under the Creative
Commons Attribution-NonCommercial-
No Derivative Works 3.0 License. To view a copy of this
license, visit http://creativecommons.org/licenses/by-nc-
nd/3.0/
Awareness of prostate cancer among patients and the general public
JM Fitzpatrick et al
352
Prostate Cancer and Prostatic DiseasesAppendix A
Survey questionnaire
Consumer survey questionnaire—final (11/10/07)
Awareness of prostate cancer among patients and the general public
JM Fitzpatrick et al
353
Prostate Cancer and Prostatic DiseasesAwareness of prostate cancer among patients and the general public
JM Fitzpatrick et al
354
Prostate Cancer and Prostatic Diseases